“…Since 2007, several clinical trials have been published on canine and feline patients treated with MC. According to the literature, this therapeutic approach has been applied to several tumour types, with splenic hemangiosarcoma ( 55 , 57 , 60–62 , 73 , 74 ) and appendicular osteosarcoma ( 68 , 71 , 76 , 80 ) being the most common treated in dogs, followed by mammary carcinoma ( 59 , 64 , 65 ), soft tissue sarcoma ( 43 , 67 , 77 ), urinary tract tumours ( 84 , 85 ), malignant oral tumours ( 66 , 70 ), primary lung carcinoma ( 69 ), hepatocellular carcinoma ( 81 ) and cerebral glioma ( 58 ). In cats, there are much fewer studies available to date, focusing mainly on mammary tumours ( 63 , 82 ).…”